Skip to main content
Year archive

BioPorto — 2026 filings

All 25 regulatory filings released by BioPorto (BIOPOR) in 2026, sourced directly from the official regulator.

25 Filings
2026 Period
2026 filings (25)
Filing Released Lang
Major Shareholder Announcement
Major Shareholding Notification
2026-04-13 Danish
Major Shareholder Announcement
Major Shareholding Notification
2026-04-13 Danish
Major Shareholder Announcement
Major Shareholding Notification
2026-04-13 English
Major Shareholder Announcement
Major Shareholding Notification
2026-04-13 English
BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC
M&A Activity
2026-04-08 Danish
BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC
M&A Activity
2026-04-08 Danish
BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC
M&A Activity
2026-04-08 English
BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC
Capital/Financing Update
2026-04-08 English
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
Regulatory Filings
2026-03-31 Danish
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
Regulatory Filings
2026-03-31 Danish
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
Regulatory Filings
2026-03-31 English
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
Regulatory Filings
2026-03-31 English
BioPorto announces the Annual Report for 2025
Earnings Release FY 2025
2026-03-26 Danish
BioPorto announces the Annual Report for 2025
Annual Report (ESEF) FY 2025
2026-03-26 English
BioPorto announces the Annual Report for 2025
Annual Report FY 2025
2026-03-26 English
BioPorto announces the Annual Report for 2025
Remuneration Information
2026-03-26 English
BioPorto announces the Annual Report for 2025
Report Publication Announcement
2026-03-26 English
BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026
Regulatory Filings
2026-03-18 Danish
BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026
Regulatory Filings
2026-03-18 Danish
BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026
Regulatory Filings
2026-03-18 English
BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026
Regulatory Filings
2026-03-18 English
BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update 
Earnings Release FY 2025
2026-02-05 Danish
BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update 
Earnings Release Q4 2025
2026-02-05 Danish
BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update 
Earnings Release Q4 2025
2026-02-05 English
BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update 
Earnings Release FY 2025
2026-02-05 English